Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6281586 | 0.93 | MAPT (0.39) | MAPTNPC1RAB9APTPN1ALDH1A1 | |
| SCHEMBL6221855 | 0.91 | NPC1 (0.42) | MAPTNPC1RAB9AALPLALDH1A1 | |
| SCHEMBL6221415 | 0.84 | NPC1 (0.42) | MAPTNPC1RAB9AALDH1A1ITGB3 | |
| SCHEMBL6289067 | 0.82 | PDE3B (0.43) | MAPTNPC1RAB9APTPN1ALDH1A1 | |
| SCHEMBL6222797 | 0.81 | NPC1 (0.54) | MAPTNPC1RAB9APTPN1ALDH1A1 | |
| SCHEMBL6289046 | 0.80 | PPARG (0.41) | PPARGPPARA | |
| SCHEMBL6286754 | 0.80 | ITGB1 (0.39) | MAPTNPC1RAB9APTPN1ALDH1A1 | |
| SCHEMBL6286984 | 0.79 | RAB9A (0.35) | MAPTNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL6284756 | 0.78 | NPR3 (0.33) | MAPTPTPN1ITGB3ITGA2BPPARG | |
| SCHEMBL6868246 | 0.77 | ITGB3 (0.43) | ITGB3ITGA2BITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838453-B2 | Antagonist derivatives of the vitronectin receptor | AVENTIS PHARMA S.A. (FR) | 2005-01-04 | — | — | US | disclosed |
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | ADGRF1, BDKRB1, ADGRE5 | MAPT 4359/4885NPC1 1519/4885RAB9A 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.